5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) †

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Highlights

•

This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients
•

It provides updates on the management of patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care
•

Updated diagnostic and treatment algorithms are also provided
•

All recommendations were compiled by a multidisciplinary group of international experts
•

Recommendations are based on available clinical evidence and the collective expert opinion of the authors

Related collections

Most cited references 144

Record: found
Abstract: found
Article: not found

Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Ahmedin Jemal, Lindsey A Torre, Rebecca Siegel … (2018)

This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.

0 comments Cited 26430 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Alfons Schmid, Sylvia Adams, Hope Rugo … (2018)

Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab.

0 comments Cited 1364 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Breast cancer

Nadia Harbeck, Frederique Penault-Llorca, Javier Cortés … (2019)

Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70-80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with distant organ metastases is considered incurable with currently available therapies. On the molecular level, breast cancer is a heterogeneous disease; molecular features include activation of human epidermal growth factor receptor 2 (HER2, encoded by ERBB2), activation of hormone receptors (oestrogen receptor and progesterone receptor) and/or BRCA mutations. Treatment strategies differ according to molecular subtype. Management of breast cancer is multidisciplinary; it includes locoregional (surgery and radiation therapy) and systemic therapy approaches. Systemic therapies include endocrine therapy for hormone receptor-positive disease, chemotherapy, anti-HER2 therapy for HER2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibitors for BRCA mutation carriers and, quite recently, immunotherapy. Future therapeutic concepts in breast cancer aim at individualization of therapy as well as at treatment de-escalation and escalation based on tumour biology and early therapy response. Next to further treatment innovations, equal worldwide access to therapeutic advances remains the global challenge in breast cancer care for the future.

0 comments Cited 824 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Ann Oncol

Journal ID (iso-abbrev): Ann. Oncol

Title: Annals of Oncology

Publisher: European Society for Medical Oncology. Published by Elsevier Ltd.

ISSN (Print): 0923-7534

ISSN (Electronic): 1569-8041

Publication date PMC-release: 23 September 2020

Publication date (Electronic): 23 September 2020

Affiliations

[1 ]Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal

[2 ]Sharett Division of Oncology, Hadassah University Hospital, Jerusalem, Israel

[3 ]Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland

[4 ]Department of Oncology and Hemato-Oncology, European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milan, Milan, Italy

[5 ]Breast Center, Clinique de Genolier, Genolier, Switzlerand

[6 ]Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France

[7 ]Latin American Cooperative Oncology Group (LACOG), Grupo Oncoclínicas, Porto Alegre, Brazil

[8 ]Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden

[9 ]Department of Medical Oncology, Salt Lake City Medical Centre, Kolkata, India

[10 ]Department of Medical Oncology, Nuovo Ospedale di Prato – Istituto Toscano Tumori, Prato, Italy

[11 ]The Pam McLean Centre, Royal North Shore Hospital, St Leonards, Australia

[12 ]Nova Medical School, Lisbon, Portugal

[13 ]Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA

[14 ]IOB Institute of Oncology, Quiron Group, Madrid & Barcelona

[15 ]Department of Oncology, Vall d´Hebron Institute of Oncology, Barcelona, Spain

[16 ]Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

[17 ]Europa Donna, The European Breast Cancer Coalition, Milan, Italy

[18 ]Interdisciplinary Oncology Service (SIC), Riviera-Chablais Hospital, Rennaz, Switzerland

[19 ]SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK

[20 ]Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

[21 ]Medical Oncology Department, BC Cancer Agency, Vancouver, Canada

[22 ]Breast Cancer Expert Center, University Cancer Institute APHP, Sorbonne University, Paris, France

[23 ]Brustkrebs Deutschland e.V., Munich, Germany

[24 ]Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany

[25 ]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

[26 ]Department of Oncology, Sheba Medical Center, Ramat Gan, Israel

[27 ]Breast Cancer Welfare Association Malaysia, Petaling Jaya, Malaysia

[28 ]NHMRC Clinical Trials Centre, Sydney Medical School, Sydney, Australia

[29 ]Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea

[30 ]Susan Smith Center for Women's Cancers – Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA

[31 ]Metastatic Breast Cancer Network, Inverness, USA

[32 ]Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru

[33 ]Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

[34 ]Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan

[35 ]Medical School, Geneva University Hospital, Geneva, Switzerland

[36 ]Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain

[37 ]Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand

[38 ]University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, France

[39 ]Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

[40 ]Division of Oncology, Stanford School of Medicine, Stanford, USA

[41 ]Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany

[42 ]Oncology Research Unit, Belong.Life, Tel Aviv, Israel

[43 ]Department of Applied Health Research in Cancer Care, The Royal Marsden Hospital NHS Foundation Trust, London, UK

[44 ]Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

[45 ]Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA

[46 ]European School of Oncology, Milan, Italy

[47 ]European School of Oncology, Bellinzona, Switzerland

Author notes

[∗ ]Correspondence to: Dr Fatima Cardoso, Breast Unit, Champalimaud Clinical Center, Av. De Brasília s/n, 1400-038 Lisbon, Portugal

Article

Publisher ID: S0923-7534(20)42460-3

DOI: 10.1016/j.annonc.2020.09.010

PMC ID: 7510449

PubMed ID: 32979513

SO-VID: df67e8aa-d2de-4a23-b164-ae6318ee1b94

License:

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

History

Date received : 21 August 2020

Date revision received : 15 September 2020

Date accepted : 16 September 2020

Comments

Comment on this article

scite_

Cited by 415

See all cited by

Most referenced authors 2,784

See all reference authors

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) ^†

Read this article at

Highlights

Related collections

Karger: Oncology

Most cited references 144

Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Breast cancer

Author and article information

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 372

Cited by 415

Most referenced authors 2,784